Akademik Veri Yönetim Sistemi
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, cilt.34, sa.1, ss.28-34, 2024 (SCI-Expanded)
We evaluated the prognostic value of the hemoglobin albumin lymphocyte and platelet (HALP) score and inflammatory index in patients with metastatic castration -resistant prostate cancer (mCRPC) treated with abiraterone and enzalutamide. In this retrospective study, 136 patients with mCRPC were treated with enzalutamide and abiraterone between January 2018 and March 2023; all data were collected from the hospital database. The HALP score and neutrophil-to-lymphocyte ratio (NLR) were calculated from baseline blood tests, and their impacts on progression -free survival (PFS) and overall survival (OS) were analyzed. Patients with lower HALP scores (<= 23.78) exhibited a significantly reduced OS of 31.2 months compared with those with higher scores (> 23.78, OS: 63.9 months). Similarly, patients with a higher NLR (> 2.15) showed a poorer OS of 38.4 months compared with those with a lower NLR (<= 2.15, OS: 70.1 months). The results were significant in terms of PFS. Patients with lower HALP scores had a PFS of 22.9 months, whereas those with higher scores had a longer PFS of 43.2 months. For NLR, patients with a score <= 2.15 had a PFS of 43.0 months, whereas those with scores > 2.15 had a PFS of 33.5 months. These findings, supported by ROC curve analysis, Kaplan-Meier estimates, and Cox regression analysis, underscore the significance of the HALP score and NLR as prognostic factors. This study highlights the HALP score and NLR as effective, low-cost prognostic markers for patients with mCRPC undergoing treatment with next -generation anti -androgens. These biomarkers can predict patient outcomes and guiding treatment strategies.